Kairos Pharma, Ltd.
KAPA
$0.34
-$0.02-5.28%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.67M | 3.44M | 3.83M | 3.38M | 2.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.00M | 5.57M | 5.60M | 4.55M | 3.32M |
| Operating Income | -6.00M | -5.57M | -5.60M | -4.55M | -3.32M |
| Income Before Tax | -5.84M | -5.45M | -5.06M | -4.71M | -3.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.84 | -5.45 | -5.06 | -4.71 | -3.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.84M | -5.45M | -5.06M | -4.71M | -3.54M |
| EBIT | -6.00M | -5.57M | -5.60M | -4.55M | -3.32M |
| EBITDA | -5.84M | -5.41M | -5.44M | -4.39M | -3.16M |
| EPS Basic | -0.30 | -0.30 | -0.30 | -0.33 | -0.27 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.22 | -0.24 | -0.20 |
| EPS Diluted | -0.30 | -0.30 | -0.30 | -0.33 | -0.27 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.22 | -0.24 | -0.20 |
| Average Basic Shares Outstanding | 79.28M | 74.14M | 66.68M | 57.39M | 50.73M |
| Average Diluted Shares Outstanding | 79.28M | 74.14M | 66.68M | 57.39M | 50.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |